stockrow
Saturday 7 November 2026
Export PTHS’s income statement to Excel — free account
Pelthos Therapeutics Inc.
PTHS Healthcare Biotechnology
Pelthos Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.8 million.
- EPS
- −23.1%
- Free cash flow
- −1,615.0%
- Total debt
- +2,692.8%
Quarter to June 2026, against a year earlier
9.51
0.21
+2.26%
Follow PTHS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 17 | 43 | — | 6 | 11 | 16 | (2.1%) | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | 76.25 | 78.59 | — | ||||||
| EBT | — | — | — | — | — | (1) | (2) | (7) | (8) | (51) | (94) | +203.8% | ||||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (301.91) | (216.56) | (301.9) pt | ||||||
| Net income | — | — | — | — | — | (1) | (2) | (7) | (8) | (43) | (86) | +192.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 8.93 | 12.23 | n/m | |||||
| Earnings | — | — | — | — | — | — | (56.52) | (57.80) | (14.30) | (23.04) | (26.27) | (25.9%) | ||||||
| Cash flow | — | — | — | — | — | 0.00 | (36.03) | (7.68) | (10.39) | (12.01) | (11.95) | n/m | ||||||
| Capex | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.05) | (0.08) | n/m | ||||||
| Free cash flow | — | — | — | — | — | 0.00 | (36.03) | (7.68) | (10.39) | (12.07) | (12.03) | n/m | ||||||
| Book value | — | — | — | — | — | 0.00 | (85.21) | (50.47) | (4.87) | 20.68 | (0.42) | n/m | ||||||
| Shares, m | — | — | — | — | — | — | 0 | 0 | 1 | 2 | 3 | +251.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | 0.78 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | 2.55 | 0.00 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | 1.88 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (5.08) | (1.91) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (2) | (2) | (1) | (6) | (23) | (42) | +94.1% | |||||
| Capex | — | — | — | — | — | — | — | — | — | 0 | 0 | — | ||||||
| Free cash flow | — | — | — | — | — | (2) | (2) | (1) | (6) | (23) | (43) | +94.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | (3) | (4) | (6) | (3) | 27 | 31 | n/m | |||||
| Net debt | — | — | — | — | — | — | 0 | 1 | 2 | 13 | 45 | +202.4% | ||||||
| Shareholders’ equity | — | — | — | — | — | (4) | (4) | (6) | (3) | 39 | (2) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (8,924.14) | (9,743.63) | (1,085.71) | (65.75) | (125.04) | (65.7) pt | |||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (38.76) | (82.34) | (38.8) pt | ||||||
| ROE | — | — | — | — | — | 0.00 | 66.57 | 145.42 | 173.72 | (239.55) | 2,161.07 | (239.5) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 4 | 11 | 92 | — | +379.6% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.18 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Pelthos Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IBO Impact Biomedical Inc. | $38.0M | — (loss-making) | — | −57.14% (below 0%: shrinking) | n/m | +167.72% (above 0%: growing) | 66.67% | (23,400.00%) | Compare |
| ELTX Elicio Therapeutics, Inc. | $37.9M | — (loss-making) | — (loss-making) | −55.27% (below 0%: shrinking) | n/m | +8.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRCE Grace Therapeutics, Inc. | $37.5M | — (loss-making) | — (loss-making) | +5,127.27% (above 0%: growing) | n/m | −78.85% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALDX Aldeyra Therapeutics, Inc. | $37.2M | — (loss-making) | — | — | n/m | +46.09% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TVGN Tevogen Inc. | $36.2M | — (loss-making) | — | — | n/m | +5.78% (above 0%: growing) | — | 0.00% | Compare |
| PTHS Pelthos Therapeutics Inc. | $35.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | |
| VERU Veru Inc. | $35.1M | — (loss-making) | — (loss-making) | +99.23% (above 0%: growing) | n/m | +0.27% (above 0%: growing) | 67.84% | 0.00% | Compare |
| LIANY LianBio Sponsored ADR | $34.2M | 0.0× | — | — | n/m | +1,107.59% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRDX GridAI Technologies Corp. | $33.3M | — (loss-making) | — | — | n/m | −2,640.98% (below 0%: shrinking) | (42.49%) | (15,258.21%) | Compare |
| Median of peers | $36.7M | — | — | +21.98% | — | +7.28% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 18 August 2026
Ownership
Directors and executive officers, together
16.40%
Ligand Pharmaceuticals Incorporated
49.90%
3i, LP
8.30%
Murchinson Ltd.
7.30%
Ikarian Capital, LLC
6.70%
Ezra Friedberg
5.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement